Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Adaptive Biotechnologies (ADPT) Tops Q2 EPS by 2c; Offers FY23 Revenue Guidance
August 2, 2023 4:36 PM EDTAdaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.33), $0.02 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $44.87 million.
GUIDANCE:
Adaptive Biotechnologies sees FY2023 revenue of $205-215 million, versus the consensus of... More
Adaptive Biotechnologies (ADPT) Tops Q2 EPS by 2c; Offers FY23 Revenue Guidance
August 2, 2023 4:09 PM EDTAdaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.33), $0.02 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $44.87 million.
GUIDANCE:
Adaptive Biotechnologies sees FY2023 revenue of $205-215 million, versus the consensus of... More
